湖南华纳大药厂股份有限公司2025年度业绩快报公告

Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 1.516 billion yuan, representing a year-on-year increase of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a significant year-on-year growth of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, which reflects a decrease of 6.01% compared to the previous year [1] - Total assets at the end of the reporting period reached 3.053 billion yuan, marking a year-on-year increase of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, up 13.44% year-on-year [1] Performance Drivers - The increase in revenue was primarily driven by growth in sales of formulation products, raw materials, intermediate products, and technical service income [2] - The rise in net profit attributable to the parent company was mainly influenced by investment income [2] - The decline in net profit after deducting non-recurring gains and losses was attributed to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit would have been 182 million yuan, an increase of 31.57% year-on-year [2] Significant Changes in Financial Metrics - Operating profit increased by 51.53% year-on-year, while total profit rose by 51.88% [3] - The basic earnings per share grew by 47.20% year-on-year, largely due to the strategic investment and restructuring of Shanghai Zhigen Pharmaceutical Technology Co., Ltd., which resulted in the company no longer consolidating it in its financial statements [3] - The company's share capital increased by 40.00% due to a capital reserve conversion, raising the total shares from 93.8 million to 131.32 million [3]